| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Aug, 2026 | Aug, 2026 |
| Sales | 3,490,834 | 3,349,652 | 2,940,455 | 0 | 0 |
| Sales Growth | +4.21% | +13.92% | unch | unch | unch |
| Net Income | 373,776 | 151,699 | -146,916 | 0 | 0 |
| Net Income Growth | +146.39% | +203.26% | unch | unch | unch |
Apotex Health Corp (APTX.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Apotex Health Corp is a Canadian-based health company with a broad portfolio of generic, biosimilar and branded pharmaceuticals, as well as branded consumer health and wellness products. Its business lines include Conventional Generics, Specialty Generics and Brands & Biosimilars. The maximum revenue is derived from the Conventional Generics business, which are off-patent, small molecule oral solid dose pharmaceuticals that are bioequivalent to branded pharmaceuticals. It has three geographic operating segments: (i) Canada; (ii) the U.S.; and (iii) International. The majority of revenue is derived from Canada.
Fiscal Year End Date: 03/31